Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2025 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 05, 2025 16:05 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 04, 2025 08:37 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 03, 2025 16:35 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Proposed Underwritten Public Offering

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 03, 2025 11:33 ET | Source: Artelo Biosciences

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 03, 2025 08:45 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed...
August 25, 2025 07:55 ET | Source: Artelo Biosciences

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances...
August 13, 2025 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
August 11, 2025 09:15 ET | Source: Artelo Biosciences

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE...
August 04, 2025 07:30 ET | Source: Artelo Biosciences

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s...